Frovatriptan and Rizatriptan Economic EVAluation: the FREEVA study

Lisotto, Carlo; Guidotti, Mario; Zava, Dario; Savi, L

doi:10.1186/1129-2377-14-96

Cited by 7 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We recommend caution, as this is a cross-sectional study, and longitudinal within-person acute treatment optimization and its relationship to LPT were not assessed. Results of randomized controlled trials of triptans suggest that use of effective treatments can reduce LPT 46–48 . In addition, patients who do not respond to triptans have greater losses in work productivity than triptan responders 49 .…”

Section: Discussionmentioning

confidence: 99%

“…Results of randomized controlled trials of triptans suggest that use of effective treatments can reduce LPT. [46][47][48] In addition, patients who do not respond to triptans have greater losses in work productivity than triptan responders. 49 Preventive treatment of migraine has also been associated with reductions in lost work productivity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Optimized Acute Treatment of Migraine Is Associated With Greater Productivity in People With Migraine

Buse

Nahas

Stewart³

et al. 2023

J Occup Environ Med

View full text Add to dashboard Cite

Objective: This study aimed to ascertain whether level of optimization of acute treatment of migraine is related to work productivity across the spectrum of migraine. Methods: Data were from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study, an internet-based longitudinal survey. Respondents with migraine who reported full-time employment and use of ≥1 acute prescription medication for migraine were included. We determined relationships among lost productive time (LPT; measured with the Migraine Disability Assessment Scale), acute treatment optimization (Migraine Treatment Optimization Questionnaire-), and monthly headache days (MHDs). Results: There was a direct relationship between LPT and MHD category. Greater acute treatment optimization was associated with lower total LPT, less absenteeism, and less presenteeism within each MHD category. Conclusions: Optimizing acute treatment for migraine may reduce LPT in people with migraine and reduce indirect costs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Optimized Acute Treatment of Migraine Is Associated With Greater Productivity in People With Migraine

Buse

Nahas

Stewart³

et al. 2023

J Occup Environ Med

View full text Add to dashboard Cite

show abstract

“…Migraine has a large economic impact on society, with two-thirds of the financial burden linked to indirect costs, such as effect on productivity at work. 48 , 49 An economical advantage of frovatriptan among the oral triptans has been suggested, with model analysis based on the human capital approach showing frovatriptan to be significantly more cost-effective than rizatriptan in particular. 49 This outcome is likely due to lower acquisition cost of frovatriptan, the need for fewer doses, and loss of fewer working hours.…”

Section: Frovatriptan In the Acute Treatment Of Migraine: Evidence Frmentioning

confidence: 99%

“… 49 This outcome is likely due to lower acquisition cost of frovatriptan, the need for fewer doses, and loss of fewer working hours. 49 …”

Section: Frovatriptan In the Acute Treatment Of Migraine: Evidence Frmentioning

confidence: 99%

Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine

Allais

Benedetto

2016

DDDT

View full text Add to dashboard Cite

Migraine is a common neurovascular disorder, affecting millions of people worldwide. Current guidelines recommend triptans as first-line treatment for moderate-to-severe migraine attacks. Frovatriptan is a second-generation triptan with a longer terminal elimination half-life in blood than other triptans (~26 hours). Three double-blind, randomized crossover preference studies have been recently conducted, assessing efficacy and safety of frovatriptan versus rizatriptan, zolmitriptan, and almotriptan, respectively. Frovatriptan showed favorable tolerability and sustained effect, with a significantly lower rate of relapse over 48 hours versus the other triptans. These findings were confirmed in a series of analyses of patient subsets from the three studies, including patients with menstrually related and oral contraceptive-induced migraine, hypertension, obesity, weekend migraine, as well as patients with migraine with aura. In all patient subsets analyzed, lower headache recurrence rates were observed versus the comparator triptans, indicating a more sustained pain-relieving effect on migraine symptoms. A further randomized, double-blind study demonstrated that frovatriptan given in combination with the fast-acting cyclooxygenase inhibitor dexketoprofen provided improved migraine pain-free activity at 2 hours, and gave more sustained pain-free activity at 24 hours, versus frovatriptan alone. These benefits were observed both when the combination was administered early (<1 hour after symptom onset) or late (>1 hour after onset). Different pharmacokinetic, but synergistic, properties between frovatriptan and dexketoprofen may make the combination of these agents particularly effective in migraine treatment, with rapid onset of action and sustained effect over 48 hours. These benefits, together with potential cost-effectiveness advantages versus other triptans could drive selection of the most appropriate treatment for acute migraine attacks.

show abstract

“… 54 The need for fewer doses to treat migraine has significant personal benefits as well as being cost effective. 55 …”

Section: Frovatriptanmentioning

confidence: 99%

A review of frovatriptan for the treatment of menstrual migraine

MacGregor¹

2014

IJWH

View full text Add to dashboard Cite

The objective of this review is to provide an overview of menstrual migraine (MM) and of frovatriptan and to assess clinical trial data regarding the efficacy and safety of frovatriptan for the acute and short-term prophylaxis of MM. Randomized controlled trials comparing frovatriptan with placebo or a triptan comparator for the acute or prophylactic treatment of MM were selected for review. MM affects up to 60% of women with migraine. Compared with attacks at other times of the cycle, menstrual attacks are longer, more severe, less responsive to treatment, more likely to relapse, and more disabling than attacks at other times of the cycle. No drugs are licensed for acute treatment of MM; triptans are recommended for treatment of moderate to severe attacks for menstrual and nonmenstrual attacks. Perimenstrual prophylaxis is indicated for patients with predictable MM that does not respond to symptomatic treatment alone. Treatment is unlicensed, but options include triptans, nonsteroidal anti-inflammatory drugs, and hormone manipulation. Frovatriptan is distinctive from other triptans due to its long elimination half-life of 26 hours, which confers a longer duration of action. Post hoc analyses from randomized trials of MM show similar pain relief and pain-free rates for frovatriptan compared with other triptans (2 hours pain-free: relative risk [RR] 1.27, 95% confidence interval [CI] 0.91–1.76) but significantly lower relapse rates (24 hours sustained pain-free: RR 0.34, 95% CI 0.18–0.62). Data from randomized controlled trials show a significant reduction in risk of MM in women using frovatriptan 2.5 mg once daily (RR 1.56, 95% CI 1.31–1.86) or twice daily (RR 1.98, 95% CI 1.68–2.34) for perimenstrual prophylaxis compared with placebo. The twice daily dosing was more effective than once daily (RR 1.27, 95% CI 1.11–1.46). These findings support the use of frovatriptan as a first-line acute treatment for MM and for perimenstrual prophylaxis.

show abstract

Frovatriptan and Rizatriptan Economic EVAluation: the FREEVA study

Cited by 7 publications

References 31 publications

Optimized Acute Treatment of Migraine Is Associated With Greater Productivity in People With Migraine

Optimized Acute Treatment of Migraine Is Associated With Greater Productivity in People With Migraine

Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine

A review of frovatriptan for the treatment of menstrual migraine

Contact Info

Product

Resources

About